Turret Capital announced the launch of Sable, a consumer beauty company applying biotechnology research to topical body care. Backed by pre seed investment from Turret Capital and SOSV, the brand enters the prestige beauty segment with formulations aimed at body contouring and skin vitality. Sable’s initial products are based on licensed scientific discoveries originating from Columbia University Medical Center, where preclinical studies demonstrated selective uptake of a novel compound by fat cells, enabling reductions in cell volume under laboratory conditions.
The company positions Sable to address growing demand for non invasive body aesthetics alongside wellness driven lifestyle changes influencing consumer expectations. Its topical products are intended to complement professional aesthetic procedures, support maintenance during weight management transitions, and provide targeted solutions for localized concerns. Sable’s development strategy emphasizes translating academic science into scalable consumer formulations while maintaining evidence based design. Founded by a physician entrepreneur, the company aims to differentiate within a crowded beauty market by prioritizing biological mechanisms rather than cosmetic effects alone. Turret Capital views the launch as an opportunity to bridge healthcare innovation and consumer wellness. As regulatory scrutiny and consumer sophistication increase, biotech enabled topical products may redefine dynamics across body care and aesthetic longevity segments.
Why it matters
Biotech based topical products signal convergence between life sciences and consumer beauty as innovation shifts toward evidence driven aesthetic solutions.
Source Attribution
Source: Turret Capital
